B

Bioton SA
WSE:BIO

Watchlist Manager
Bioton SA
WSE:BIO
Watchlist
Price: 4 PLN 1.27% Market Closed
Market Cap: 343.4m PLN

EV/EBITDA
Enterprise Value to EBITDA

7.1
Current
7.3
Median
5.9
Industry
Lower than median
Higher than industry value

Enterprise Value to EBITDA (EV/EBITDA) ratio is a valuation multiple that compares the value of a company, debt included, to the company’s cash earnings less non-cash expenses. EBITDA can be misleading at times, especially for companies that are highly capital intensive.

EV/EBITDA
7.1
=
Enterprise Value
361.7m PLN
/
EBITDA
50.8m PLN
All Countries
Close
EBITDA Growth EV/EBITDA to Growth
PL
B
Bioton SA
WSE:BIO
Average EV/EBITDA: 34.2
7.1
N/A N/A
IL
C
Can Fite Biopharma Ltd
TASE:CANF
Negative Multiple: -17 199 054.4 N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -195 911.8 N/A N/A
US
Abbvie Inc
NYSE:ABBV
16.3
14%
1.2
US
Amgen Inc
NASDAQ:AMGN
18.3
11%
1.7
US
Gilead Sciences Inc
NASDAQ:GILD
12.5
7%
1.8
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
23.8
16%
1.5
US
E
Epizyme Inc
F:EPE
Negative Multiple: -576.7 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
17.1
11%
1.6
AU
CSL Ltd
ASX:CSL
12.5
8%
1.6
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
165.8
N/A N/A

EV/EBITDA Forward Multiples

Forward EV/EBITDA multiple is a version of the EV/EBITDA ratio that uses forecasted EBITDA for the EV/EBITDA calculation. 1-Year, 2-Years, and 3-Years forwards use EBITDA forecasts for 1, 2, and 3 years ahead, respectively.

1-Year Forward
EV/EBITDA
N/A
2-Years Forward
EV/EBITDA
N/A
3-Years Forward
EV/EBITDA
N/A